

Solid Tumor Therapeutics Market - 2024

<https://marketpublishers.com/r/S4227F53DDE3EN.html>

Date: June 2025

Pages: 200

Price: US\$ 2,999.00 (Single User License)

ID: S4227F53DDE3EN

Abstracts

The Solid Tumor Therapeutics Market was valued at USD 210.46 billion in 2024 and is anticipated to reach by , at a CAGR of 0.077 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Solid Tumor Therapeutics Market.

This report delivers a comprehensive overview of the Solid Tumor Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Solid Tumor Therapeutics Market. The Solid Tumor Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–.

Solid Tumor Therapeutics Market Scope:

By Cancer Type

Prostate Cancer

Colorectal Cancer

Lung Cancer

Breast Cancer

Cervical Cancer

Others

By Drug Type

Carboplatin

Cisplatin

Gemcitabine

Paclitaxel

Doxorubicin

Bevacizumab

Erlotinib

Sunitinib

Everolimusa

Others

By End-user

Hospitals

Specialty Clinics

Homecare

Others

By Distribution Channel

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Key Players

Sanofi

Amgen Inc.

AstraZeneca PLC

Baxter International Inc.

Biogen Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche AG

GlaxoSmithKline PLC

Major Highlights

This report delivers a comprehensive overview of the Solid Tumor Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth

strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Solid Tumor Therapeutics Market. The Solid Tumor Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Cancer Type
- 3.2. Snippet by Drug Type
- 3.3. Snippet by End-user
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increasing Incidence of cancer
 - 4.1.2. Restraints
 - 4.1.2.1. Side effects associated with solid tumor therapeutics
 - 4.1.3. Opportunity
 - 4.1.3.1. Rising research and development activities
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19
 - 6.1.1. Scenario Before COVID-19
 - 6.1.2. Scenario During COVID-19

- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers' Strategic Initiatives
- 6.6. Conclusion

7. RUSSIA-UKRAINE WAR ANALYSIS

8. ARTIFICIAL INTELLIGENCE ANALYSIS

9. BY CANCER TYPE

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
 - 9.1.2. Market Attractiveness Index, By Cancer Type
- 9.2. Prostate Cancer*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Colorectal Cancer
- 9.4. Lung Cancer
- 9.5. Breast Cancer
- 9.6. Cervical Cancer
- 9.7. Others

10. BY DRUG TYPE

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
 - 10.1.2. Market Attractiveness Index, By Drug Type
- 10.2. Carboplatin*
 - 10.2.1. Introduction
 - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Cisplatin
- 10.4. Gemcitabine
- 10.5. Paclitaxel
- 10.6. Doxorubicin
- 10.7. Bevacizumab
- 10.8. Erlotinib

- 10.9. Sunitinib
- 10.10. Everolimus
- 10.11. Others

11. BY END-USER

- 11.1. Introduction
 - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
 - 11.1.2. Market Attractiveness Index, By End-user
- 11.2. Hospitals*
 - 11.2.1. Introduction
 - 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.3. Specialty Clinics
- 11.4. Homecare
- 11.5. Others

12. BY DISTRIBUTION CHANNEL

- 12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.2. Market Attractiveness Index, By Distribution Channel
- 12.3. Retail Pharmacies*
 - 12.3.1. Introduction
 - 12.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 12.4. Hospital Pharmacies
- 12.5. Online Pharmacies

13. BY REGION

- 13.1. Introduction
 - 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 13.1.2. Market Attractiveness Index, By Region
- 13.2. North America
 - 13.2.1. Introduction
 - 13.2.2. Key Region-Specific Dynamics
 - 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
 - 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 13.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 13.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 13.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

- 13.5.1. The U.S.
- 13.5.2. Canada
- 13.5.3. Mexico
- 13.6. Europe
 - 13.6.1. Introduction
 - 13.6.2. Key Region-Specific Dynamics
- 13.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 13.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 13.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 13.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 13.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 13.11.1. Germany
 - 13.11.2. The U.K.
 - 13.11.3. France
 - 13.11.4. Italy
 - 13.11.5. Spain
 - 13.11.6. Rest of Europe
- 13.12. South America
 - 13.12.1. Introduction
 - 13.12.2. Key Region-Specific Dynamics
- 13.13. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 13.14. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 13.15. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 13.16. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 13.17. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 13.17.1. Brazil
 - 13.17.2. Argentina
 - 13.17.3. Rest of South America
- 13.18. Asia-Pacific
 - 13.18.1. Introduction
 - 13.18.2. Key Region-Specific Dynamics
- 13.19. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 13.20. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 13.21. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 13.22. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 13.23. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 13.23.1. China
 - 13.23.2. India
 - 13.23.3. Japan

13.23.4. Australia

13.23.5. Rest of Asia-Pacific

13.23.6. Middle East and Africa

13.23.6.1. Introduction

13.23.6.2. Key Region-Specific Dynamics

13.24. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

13.25. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

13.26. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13.27. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14. COMPETITIVE LANDSCAPE

14.1. Competitive Scenario

14.2. Product Benchmarking

14.3. Company Share Analysis

14.4. Key Developments and Strategies

15. COMPANY PROFILES

15.1. Sanofi*

15.1.1. Company Overview

15.1.2. Product Portfolio and Description

15.1.3. Financial Overview

15.1.4. Key Developments

15.2. Amgen Inc.

15.3. AstraZeneca PLC

15.4. Baxter International Inc.

15.5. Biogen Inc.

15.6. Boehringer Ingelheim GmbH

15.7. Bristol-Myers Squibb Company

15.8. Eli Lilly and Company

15.9. F. Hoffmann-La Roche AG

15.10. GlaxoSmithKline PLC (*LIST NOT EXHAUSTIVE)

16. APPENDIX

16.1. About Us and Services

16.2. Contact Us

I would like to order

Product name: Solid Tumor Therapeutics Market - 2024

Product link: <https://marketpublishers.com/r/S4227F53DDE3EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S4227F53DDE3EN.html>